The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
Sven De Vos
Research Funding - Gilead Sciences
Laurie Helen Sehn
Research Funding - Gilead Sciences
Stephen P. Mulligan
Research Funding - Gilead Sciences
Martin H. Dreyling
Research Funding - Gilead Sciences
Mathias J. Rummel
Research Funding - Gilead Sciences
Pier Luigi Zinzani
Research Funding - Gilead Sciences
David Michael Johnson
Employment or Leadership Position - Gilead Sciences
Shelley Evans
Employment or Leadership Position - Gilead Sciences
Roger D. Dansey
Employment or Leadership Position - Gilead Sciences
Wayne R. Godfrey
Employment or Leadership Position - Gilead Sciences
Myron Stefan Czuczman
Research Funding - Gilead Sciences